JP2018528759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528759A5 JP2018528759A5 JP2017567294A JP2017567294A JP2018528759A5 JP 2018528759 A5 JP2018528759 A5 JP 2018528759A5 JP 2017567294 A JP2017567294 A JP 2017567294A JP 2017567294 A JP2017567294 A JP 2017567294A JP 2018528759 A5 JP2018528759 A5 JP 2018528759A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- cdr
- seq
- acid sequence
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 94
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 239000012634 fragment Substances 0.000 claims 24
- 238000000034 method Methods 0.000 claims 8
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 230000001575 pathological effect Effects 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 230000002137 anti-vascular effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 1
- 230000002055 immunohistochemical effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187204P | 2015-06-30 | 2015-06-30 | |
| US62/187,204 | 2015-06-30 | ||
| PCT/US2016/040183 WO2017004254A1 (en) | 2015-06-30 | 2016-06-29 | Anti-vascular endothelial growth factor receptor 2 (vegfr2) antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018528759A JP2018528759A (ja) | 2018-10-04 |
| JP2018528759A5 true JP2018528759A5 (OSRAM) | 2019-08-08 |
Family
ID=57609558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567294A Pending JP2018528759A (ja) | 2015-06-30 | 2016-06-29 | 抗血管内皮増殖因子受容体２（ｖｅｇｆｒ２）抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180193456A1 (OSRAM) |
| EP (1) | EP3316908A4 (OSRAM) |
| JP (1) | JP2018528759A (OSRAM) |
| KR (1) | KR20180021136A (OSRAM) |
| CN (1) | CN108025067A (OSRAM) |
| AU (1) | AU2016288192A1 (OSRAM) |
| BR (1) | BR112017027702A2 (OSRAM) |
| CA (1) | CA2990450A1 (OSRAM) |
| HK (1) | HK1254048A1 (OSRAM) |
| RU (1) | RU2018103192A (OSRAM) |
| TW (1) | TW201718641A (OSRAM) |
| WO (1) | WO2017004254A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170233480A1 (en) | 2015-12-31 | 2017-08-17 | Development Center For Biotechnology | Anti-vegfr antibody and uses thereof |
| CN106674349B (zh) * | 2017-03-07 | 2018-03-13 | 北京东方百泰生物科技有限公司 | 一种改进的抗vegfr‑2单克隆抗体 |
| TWI665213B (zh) * | 2017-06-29 | 2019-07-11 | 財團法人生物技術開發中心 | 抗人類血管內皮生長因子受體之抗體及其應用 |
| EP3768313A4 (en) | 2018-03-20 | 2022-01-05 | Yuh, Chiou Hwa | DUAL-FUNCTIONAL ANTIBODIES AGAINST VEGFR2 AND VEGFR3 DISHES |
| WO2021013061A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 一种人源化抗vegfr2抗体及其应用 |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN113480653B (zh) * | 2021-08-06 | 2022-05-06 | 朱有建 | 一种含有γδT细胞的药物组合物在治疗癌症中的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534469A (ja) * | 2007-07-25 | 2010-11-11 | アストラゼネカ アクチボラグ | Ｋｄｒ指向性標的化結合物質およびその使用 |
| CN104151429B (zh) * | 2007-11-26 | 2018-07-10 | 拜耳知识产权有限责任公司 | 抗-间皮素抗体及其用途 |
| US8128932B2 (en) * | 2009-08-17 | 2012-03-06 | Shanghai Aosaiersi Biotech Co., Ltd. | Anti-VEGFR monoclonal antibody, method of making and uses thereof |
| US9029510B2 (en) * | 2012-03-30 | 2015-05-12 | Sorrento Therapeutics, Inc. | Fully human antibodies that bind to VEGFR2 and methods of use thereof |
| ES2966030T3 (es) * | 2012-10-05 | 2024-04-18 | Kadmon Corp Llc | Anticuerpos anti-VEGFR-2/KDR humanos |
-
2016
- 2016-06-29 WO PCT/US2016/040183 patent/WO2017004254A1/en not_active Ceased
- 2016-06-29 AU AU2016288192A patent/AU2016288192A1/en not_active Abandoned
- 2016-06-29 JP JP2017567294A patent/JP2018528759A/ja active Pending
- 2016-06-29 BR BR112017027702A patent/BR112017027702A2/pt not_active Application Discontinuation
- 2016-06-29 EP EP16818720.1A patent/EP3316908A4/en not_active Withdrawn
- 2016-06-29 KR KR1020187002388A patent/KR20180021136A/ko not_active Withdrawn
- 2016-06-29 HK HK18113110.8A patent/HK1254048A1/zh unknown
- 2016-06-29 TW TW105120598A patent/TW201718641A/zh unknown
- 2016-06-29 US US15/740,790 patent/US20180193456A1/en not_active Abandoned
- 2016-06-29 RU RU2018103192A patent/RU2018103192A/ru not_active Application Discontinuation
- 2016-06-29 CN CN201680049578.3A patent/CN108025067A/zh active Pending
- 2016-06-29 CA CA2990450A patent/CA2990450A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528759A5 (OSRAM) | ||
| JP2017521054A5 (OSRAM) | ||
| JP2020501598A5 (OSRAM) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| RU2017122014A (ru) | Антитела к c10orf54 и их применения | |
| JP2017535257A5 (OSRAM) | ||
| JP2020534830A5 (OSRAM) | ||
| US11970529B2 (en) | Protein binding to fibronectin B domain | |
| JP2013056885A5 (OSRAM) | ||
| JP6875275B2 (ja) | Ｌ１ｃａｍ（ｃｄ１７）と結合する抗体などの結合分子 | |
| JP2013502913A5 (OSRAM) | ||
| JP2011207882A5 (OSRAM) | ||
| CN105209493A (zh) | 用于诊断和治疗用途的her3特异性单克隆抗体 | |
| HRP20192038T1 (hr) | Protutijela receptora anti-epidermalnog faktora rasta (egfr) | |
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| RU2019107134A (ru) | Анти-pd-1 антитела | |
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| RU2009123409A (ru) | Новые антипролиферативные антитела | |
| JP2010509931A5 (OSRAM) | ||
| JP2020534012A5 (OSRAM) | ||
| JP2020522488A5 (OSRAM) | ||
| RU2018103192A (ru) | Антитела против рецептора 2 фактора роста эндотелия сосудов (vegfr2) | |
| JP7711208B2 (ja) | Ｄｌｌ３に対する結合分子及びその使用 | |
| CN118290582A (zh) | 抗人Claudin18.2抗体及其应用 | |
| JP2009544574A5 (OSRAM) |